D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
Rhea-AI Summary
Jupiter Neurosciences (Nasdaq:JUNS), a clinical-stage biopharma focused on CNS disorders and neuroinflammation, closed a registered direct offering of 7,142,858 common shares, generating approximately $2.0 million in gross proceeds. D. Boral Capital acted as exclusive placement agent under an effective Form S-3 shelf registration.
AI-generated analysis. Not financial advice.
Positive
- Approximately $2.0 million gross proceeds raised in registered direct offering
- Ability to issue shares under effective Form S-3 shelf registration
- Engagement of D. Boral Capital as exclusive placement agent for the transaction
Negative
- Issuance of 7,142,858 new common shares increases total shares outstanding
News Market Reaction – JUNS
On the day this news was published, JUNS declined 3.28%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.5% during that session. Argus tracked a trough of -17.0% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $359K from the company's valuation, bringing the market cap to $10.59M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner flagged 2 peers moving down (median move -11.6%) without news, indicating some broader biotech pressure, but JUNS-specific direction relative to them is not defined in the data.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 21 | Registered direct closing | Neutral | -12.2% | Closing of $2.0M registered direct offering of 7,142,858 common shares. |
| May 20 | Registered direct pricing | Neutral | +10.3% | Pricing of $2.0M registered direct offering under effective Form S-3 shelf. |
Offering-related headlines over the past week produced mixed single-day reactions, with an average move of -0.97% around such financing news.
Recent history around Jupiter’s financing shows two closely linked offering events. On May 20, 2026, the company announced pricing of a registered direct offering of 7,142,858 shares for about $2.0 million in gross proceeds, followed by a closing announcement on May 21, 2026 for the same deal. Those updates triggered single-day moves of +10.25% and -12.19%, underscoring that market responses to dilution and funding headlines have been volatile.
Historical Comparison
Past offering headlines for JUNS (2 events) saw an average move of -0.97%, showing financing news has driven modest but volatile single-day reactions.
Offering-related news progressed from pricing to closing of the same $2.0 million registered direct transaction, executed under the active Form S-3 shelf.
Regulatory & Risk Context
An effective Form S-3 shelf filed on April 15, 2026 permits Jupiter to issue up to $100,000,000 of various securities via prospectus supplements, one of which was used for this $2.0 million registered direct. The shelf has been tapped multiple times, with 6 recorded usages, indicating an established mechanism for follow-on capital raises.
Market Pulse Summary
This announcement details the execution of a previously disclosed registered direct offering, adding 7,142,858 common shares for gross proceeds of about $2.0 million. The deal draws on an effective Form S-3 shelf and follows regulatory filings outlining net proceeds of roughly $1,685,000 and a post-offering share count of 43,424,110. Investors may track how this capital supports Jupiter’s programs relative to its cash balance of $2,362,749 and ongoing financing needs.
Key Terms
registered direct offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
securities purchase agreement financial
placement agent financial
u.s. securities and exchange commission regulatory
prospectus regulatory
AI-generated analysis. Not financial advice.
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately
D. Boral Capital LLC acted as the Exclusive Placement Agent for the Offering.
The shares of common stock were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on April 24, 2026.
A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC. Once filed, it was available on the SEC's website at http://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at dbccapitalmarkets@dboralcapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL(TM) -- a proprietary, enhanced bioavailability resveratrol formulation -- is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia (TM), a consumer longevity supplement. The acquisition of ALA-002 U.S. rights further strengthens the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, please visit www.jupiterneurosciences.com.
About D. Boral Capital
D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.
A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately
D. Boral Capital is a member of FINRA and SIPC.
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K filed on April 1, 2026. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For more information, please contact:
Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
ir@jupiterneurosciences.com
D. Boral Capital LLC
Email: dbccapitalmarkets@dboralcapital.com
Telephone: +1 (212) 970-5150
SOURCE: D. Boral Capital
View the original press release on ACCESS Newswire